Lignocain B. Braun Melsungen

Lidocaine, the active ingredient in Lignocain, is a local anesthetic presented as a sterile solution for epidural, intradermal, and intravenous use. It provides rapid, reversible loss of sensation to facilitate minor surgical procedures, epidural analgesia, intravenous regional anesthesia, and intradermal skin testing. GNH USA supplies Lignocain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Lignocain is a local anesthetic that blocks nerve impulse transmission in targeted tissues. - Minor surgical procedures: provides localized numbness to enable pain‑free incisions and manipulation. - Epidural analgesia: delivers segmental anesthesia for labor, postoperative pain control, or chronic pain management. - Intravenous regional anesthesia (Bier block): produces temporary limb anesthesia for short surgical interventions. - Intradermal skin testing: creates a controlled area of numbness to assess hypersensitivity reactions.

Lignocain may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Tingling or numbness at the injection site - Mild dizziness or light‑headedness - Nausea or vomiting - Transient headache - Localized swelling or erythema

Serious or Rare Side Effects: - Cardiac arrhythmias or conduction disturbances - Seizures or central nervous system depression - Respiratory depression or apnea - Severe allergic reactions including anaphylaxis - Methemoglobinemia in susceptible individuals

When using Lignocain, clinicians should observe several safety measures. - Assess patient allergy: verify no known hypersensitivity to lidocaine or amide‑type anesthetics. - Monitor cardiac function: observe ECG and blood pressure during high‑dose epidural or intravenous administration. - Use lowest effective concentration: adjust dose to achieve desired anesthesia while minimizing systemic exposure. - Avoid in severe hepatic impairment: reduced metabolism may increase toxicity risk. - Store at room temperature: keep in original container, protect from light and moisture.

Lignocain can interact with other medications, altering its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - Beta‑blockers (e.g., propranolol) combined with high‑dose lidocaine: increased risk of severe bradycardia and conduction block.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): can raise plasma lidocaine levels. - CYP1A2 inducers (e.g., carbamazepine, smoking): may reduce therapeutic effect. - Concurrent use of other local anesthetics: cumulative toxicity risk, especially with large total doses.